MYCELX TECHNOLOGIES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57 GBX | -.--% |
|
+6.54% | -8.06% |
| Apr. 24 | EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles | AN |
| Apr. 11 | MyCelx commends new national drinking water standards for US | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Environmental Services & Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.06% | 16.41M | - | ||
| +16.15% | 83.43B | C+ | ||
| +16.25% | 60.38B | A- | ||
| +13.88% | 23.12B | - | ||
| +8.56% | 10.22B | C+ | ||
| +16.65% | 10.41B | A- | ||
| -12.64% | 5.93B | B- | ||
| +27.47% | 4.92B | B+ | ||
| +13.73% | 4.49B | B+ | ||
| -5.29% | 3B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MYX Stock
- Ratings MYCELX Technologies Corporation
